| Title |
Treatments for relapsing–remitting multiple sclerosis: summarising current information by network meta-analysis
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, November 2011
|
| DOI | 10.1007/s00228-011-1141-1 |
| Pubmed ID | |
| Authors |
Fabiola Del Santo, Dario Maratea, Valeria Fadda, Sabrina Trippoli, Andrea Messori |
| Abstract |
Oral drugs for relapsing-remitting multiple sclerosis (RRMS) have been recently investigated and, one of these, fingolimod, is already available in several countries. In this framework, an analysis of the data in terms of the comparative effectiveness for all treatments thus far approved for RRMS can be useful to reappraise their place in therapy. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Norway | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 3 | 4% |
| United Kingdom | 2 | 2% |
| Unknown | 76 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 13 | 16% |
| Researcher | 12 | 15% |
| Student > Ph. D. Student | 11 | 14% |
| Student > Master | 8 | 10% |
| Student > Bachelor | 7 | 9% |
| Other | 17 | 21% |
| Unknown | 13 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 36% |
| Agricultural and Biological Sciences | 10 | 12% |
| Neuroscience | 7 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Economics, Econometrics and Finance | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 19 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2012.
All research outputs
#12,852,855
of 22,664,644 outputs
Outputs from European Journal of Clinical Pharmacology
#1,826
of 2,549 outputs
Outputs of similar age
#83,925
of 141,660 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#12
of 20 outputs
Altmetric has tracked 22,664,644 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,549 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 141,660 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.